KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Short term Debt data on record, last reported at $6.8 million in Q4 2025.

  • For Q4 2025, Short term Debt fell 93.24% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $6.8 million, down 93.24%, while the annual FY2025 figure was $6.8 million, 93.24% down from the prior year.
  • Short term Debt reached $6.8 million in Q4 2025 per AMRX's latest filing, down from $7.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $290.0 million in Q1 2025 and bottomed at $6.8 million in Q4 2025.
  • Average Short term Debt over 5 years is $91.9 million, with a median of $41.0 million recorded in 2021.
  • Peak YoY movement for Short term Debt: soared 640.52% in 2024, then tumbled 96.79% in 2025.
  • A 5-year view of Short term Debt shows it stood at $47.9 million in 2021, then plummeted by 37.4% to $30.0 million in 2022, then grew by 13.9% to $34.1 million in 2023, then skyrocketed by 193.04% to $100.0 million in 2024, then crashed by 93.24% to $6.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $6.8 million in Q4 2025, $7.2 million in Q3 2025, and $290.0 million in Q2 2025.